PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11802204-0	2002	Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine.	gemcitabine	78-89	tumor protein p53	Homo sapiens	31-34	
11802204-3	2002	The present study was performed to gain insight into the role of p53 status on the cytotoxicity of gemcitabine on cancer cells.	gemcitabine	99-110	tumor protein p53	Homo sapiens	65-68	
11802204-11	2002	This corresponded with suppression of Bcl-2 and Bcl-X/L expression in wt-p53 cells exposed to gemcitabine whereas Bcl-2 levels remained stable and Bcl-X/L levels increased in mut-p53 cells exposed to gemcitabine.	gemcitabine	94-105	tumor protein p53	Homo sapiens	73-76	
11802204-12	2002	We conclude that the p53 status of cancer cells influences their sensitivity to gemcitabine cytotoxicity.	gemcitabine	80-91	tumor protein p53	Homo sapiens	21-24	
11802204-13	2002	Our evidence suggests that loss of p53 function leads to loss of cell cycle control and alterations in the apoptotic cascade, conferring resistance to gemcitabine in cancer cell lines displaying a mut-p53.	gemcitabine	151-162	tumor protein p53	Homo sapiens	35-38	
11802204-13	2002	Our evidence suggests that loss of p53 function leads to loss of cell cycle control and alterations in the apoptotic cascade, conferring resistance to gemcitabine in cancer cell lines displaying a mut-p53.	gemcitabine	151-162	tumor protein p53	Homo sapiens	201-204